Dutch biotechnology company Crucell N.V. (Euronext, NASDAQ: CRXL) and DSM Biologics, a business unit of DSM Pharmaceutical Products (a business group of Royal DSM NV) announced today that they will strengthen and expand the development of the PER.C6® protein and monoclonal antibody licensing business. The two companies will create an integrated solution for the production of recombinant proteins and monoclonal antibodies on PER.C6® in order to increase licensing and royalty income and accelerate the development and roll-out of the PER.C6® technology platform in the market.
